Viewing Study NCT03347292


Ignite Creation Date: 2025-12-24 @ 3:24 PM
Ignite Modification Date: 2026-01-04 @ 2:00 PM
Study NCT ID: NCT03347292
Status: COMPLETED
Last Update Posted: 2023-07-25
First Post: 2017-11-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Sponsor: Bayer
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module